COVID-19 in Pregnancy - Volume II
Submission Deadline: 15 Sep 2024
Guest Editor

Department of Life Sciences, Health, and Health Care Professions, Link Campus University, Rome, Italy
Interests: gynaecopathology; gynaecological oncology; molecular oncology; human papilloma virus; PAP smear; breast cancer; target therapy; precision oncology; endocrine disruptors; SIDS; COVID-19
Special Issue in IMR Press journals
Special Issue in COVID-19 in Pregnancy
Special Issue Information
Dear Colleagues,
It was 11 March 2020, when the World Health Organization declared Coronavirus Disease 2019 (COVID-19) a pandemic, which would later shock the entire globe. Among the people most vulnerable to infection are pregnant women due to rearrangements in the immune and angiotensin systems. To combat COVID-19, specific and innovative vaccines have been launched in record time by conditional marketing authorization, whose long-term effects on the mother, fetus and newborn are not yet known. There are still limited data on the implications of COVID-19 infections for labor, although an increased risk of preterm delivery has been reported. Early studies indicated no evidence for vertical mother-to-child transmission of COVID-19 in late pregnancy, but more recent findings show that vertical transmission can occur in some cases. The aim and scope of this Special Issue is therefore to collect as much up-to-date information as possible on COVID-19 in pregnancy through a multidisciplinary approach.
Dr. Luca Roncati
Guest Editor
Keywords
- COVID-19
- SARS-CoV-2
- Th1
- Th2
- ACE
- ACE2
- angiotensin
- pregnancy
- preterm labor
- miscarriage
- placenta
- fetus
- fetoplacental pathology
- vaccines
